BioNTech (NASDAQ:BNTX) Announces Earnings Results, Beats Estimates By $0.18 EPS

BioNTech (NASDAQ:BNTX) issued its earnings results on Tuesday. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.18, FiscalAI reports. BioNTech had a negative net margin of 17.91% and a negative return on equity of 3.03%. The company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $941.99 million.

BioNTech Stock Up 0.7%

Shares of NASDAQ BNTX opened at $102.16 on Tuesday. BioNTech has a 1 year low of $81.20 and a 1 year high of $124.00. The firm’s 50 day moving average price is $106.95 and its 200 day moving average price is $103.02. The firm has a market cap of $23.00 billion, a P/E ratio of -38.84 and a beta of 1.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.02 and a current ratio of 7.12.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $140.00 price target on shares of BioNTech in a research note on Thursday, December 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research note on Friday, January 9th. The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and upped their target price for the company from $115.00 to $142.00 in a research note on Friday, January 16th. UBS Group upgraded BioNTech to a “hold” rating in a report on Thursday, December 4th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $151.00 price target on shares of BioNTech in a research report on Wednesday, December 3rd. Eleven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $140.10.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of BNTX. EFG International AG purchased a new stake in shares of BioNTech in the fourth quarter valued at $29,000. Caitong International Asset Management Co. Ltd increased its stake in BioNTech by 520.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after purchasing an additional 260 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after buying an additional 305 shares during the period. NewEdge Advisors LLC acquired a new stake in BioNTech in the 1st quarter worth about $167,000. Finally, Osaic Holdings Inc. boosted its stake in BioNTech by 27.3% in the 2nd quarter. Osaic Holdings Inc. now owns 1,949 shares of the company’s stock worth $208,000 after buying an additional 418 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.